ABSTRACT We report here the full coding sequence of nine paramyxovirus genomes, including two full-length mumps virus genomes (genotypes G and H) and seven measles virus genomes (genotypes B3 and D4, D8, and D9), from respiratory samples of patients from California, Virginia, and Alabama obtained between 2010 and 2014.
M
embers of the Paramyxoviridae family of single-stranded, negative-sense, nonsegmented RNA viruses are causative agents of highly transmissible diseases in humans, including measles (genus Morbillivirus) and mumps (genus Rubulavirus) (1, 2) . Infections are generally mild but can lead to serious complications, including secondary infections causing pneumonias or gastrointestinal infections in measles cases and aseptic meningitis, encephalitis, and orchitis in mumps cases (3, 4) . Vaccination eliminated measles from the United States; however, outbreaks have occurred due to importation from countries in which measles is endemic (5) . In recent years, there have been numerous mumps outbreaks in the United States (4). Genetic characterization of circulating measles and mumps viruses is vital for surveillance. The mumps virus (MuV) genome is 15,384 nucleotides (nt) in length, with the 12 mumps genotypes delineated based on SH and HN gene sequences (6) (7) (8) . The measles virus (MeV) genome is 15,894 nt in length and assigned to one of 24 genotypes based on the highly variable 450-nt coding for the carboxyl terminus of the nucleocapsid protein (N-450) (7, 9) . Though genotyping protocols are well established, SH and N-450 sequences often do not provide sufficient resolution to accurately map transmission pathways. Application of next-generation sequencing (NGS) methods will expand the amount of sequence information available for MuV and MeV. The genomic sequences reported here were generated at a CDC/Association of Public Health Laboratories (APHL) training workshop to assist the Vaccine Preventable Disease Reference Centers in implementing NGS protocols (5) .
Viral isolates of MeV and MuV were passaged in Vero/hSLAM cells, and clinical specimens containing MeV were filtered and nuclease-treated prior to RNA extraction using the QIAmp viral RNA mini kit with an on-column DNase treatment (Qiagen). Random amplicons were prepared from viral RNA using sequence-independent singleprimer amplification and size-selected using AMPure XP beads (Beckman Coulter, Inc.) (10) . Nextera XT libraries were prepared and sequenced on an Illumina MiSeq 500-cycle paired-end run. Sequence data were processed through an in-house bioinformatics pipeline modified from a previous study (11) , and genomes were annotated using Sequin. The MuV genomes were genotypes H (MuVs/Virginia.USA/10.12) and G (MuVs/ California.USA/40.11). MuVs/California.USA/40.11 was from a university outbreak in California in 2011 (12) , in which the source patient traveled to western Europe during the exposure period. Mumps virus genotype G is the most commonly detected genotype in the United States, Canada, and western Europe (1, 6). The predicted I protein, of unknown function (13), for MuVs/California.USA/40.11 ends prematurely by six amino acids. Truncated I proteins have been observed in at least 11 other MuV sequences deposited in GenBank. For MeV, two sequences were D4 genotype (MVs/ California.USA/47.13 and MVi/California.USA/16.12), three were genotype B3 (MVs/ California.USA/05.14, MVs/California.USA/08.14/3, and MVs/Alabama.USA/13.14), one was genotype D8 (MVs/California.USA/49.10), and one sequence was genotype D9 (MVi/California.USA/19.10). To our knowledge, MVi/California.USA/19.10 represents the first complete genomic sequence for genotype D9.
The nine sequences described here will expand the sequence databases for MeV and MuV. These data help to improve the resolution of virologic surveillance for MuV and MeV and develop more robust methods to support molecular epidemiological studies (13) (14) (15) . 
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